early phase battery (CogState Ltd)
90
Structured Review
CogState Ltd
early phase battery
Early Phase Battery, supplied by CogState Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/early+phase+battery/early+phase+battery/pm39394685-57-11-11
Average 90 stars, based on 1 article reviews
Early Phase Battery, supplied by CogState Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/early+phase+battery/early+phase+battery/pm39394685-57-11-11
Average 90 stars, based on 1 article reviews
early phase battery - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Battery:Article Title: Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trial. Article Snippet: Background: Zuranolone is an oral, once-daily, 14-day treatment course approved for adults with postpartum depression in the United States.. Aims: To assess cognitive effects, pharmacokinetics, and safety of zuranolone, alone or with alprazolam/ethanol.. Methods: This was a phase 1, two-part, two-period, randomized, double-blind, placebo-controlled crossover trial. Article Title: The central nervous system effects of the partial GABA-Aα 2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males Article Snippet: .. The Article Title: Neuroactive steroids, compositions, and uses thereof Article Snippet: To determine the pharmacokinetic (PK) profile of multiple doses of Compound 9 Oral Solution as assessed by the calculation of standard PK parameters; To investigate concentrations of Compound 9 metabolites in plasma and urine after multiple oral dosing; To investigate the pharmacodynamic effects of multiple doses of Compound 9 Oral Solution as assessed by psychomotor testing (Cogstate Early Phase Battery consisting of Detection Task, Identification Task, One Card Learning Task, and Groton Maze Learning Test), mood, anxiety and depression (the Bond-Lader VAS and Hospital Anxiety and Depression Scale), drug likeability (the Drug Effects Questionnaire—5), and electroencephalography (EEG) with eye tracking; To investigate whether Compound 9 Oral Solution induces the metabolism of drugs metabolized via the CYP3A4 and CYP2B6 pathways as assessed by dosing simvastatin and bupropion before and after exposure to Compound 9 in the Drug-Drug-Interaction (DDI) Cohort. .. To determine the pharmacokinetic (PK) profile of multiple doses of Compound 9 Oral Solution as assessed by the calculation of standard PK parameters; To investigate concentrations of Compound 9 metabolites in plasma and urine after multiple oral dosing; To investigate the pharmacodynamic effects of multiple doses of Compound 9 Oral Solution as assessed by psychomotor testing ( Article Title: The central nervous system effects of the partial GABA-Aα 2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males Article Snippet: CogState Battery The CogState Early Phase Battery is a computer administered cognitive test battery that takes about 12 min to perform. .. It is designed to provide objective information regarding possible drug effects on cognitive function 34 .The Article Title: The central nervous system effects of the partial GABA-Aα 2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males Article Snippet: .. CogState Battery The Article Title: Brexpiprazole: A Review in Schizophrenia. Article Snippet: Brexpiprazole (Rxulti®, Rexulti®) is an oral atypical antipsychotic agent approved for the treatment of schizophrenia in the EU (in adult patients) and the USA, as well as in some other countries, including Japan.. Like aripiprazole, it is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2A receptors.. However, brexpiprazole displays less intrinsic activity at D2 receptors and, coupled with actions at 5HT1A, 5HT2A and noradrenaline α1B receptors that are at least as potent as its action at D2 receptors, is predicted to demonstrate a lower propensity for activating adverse events and extrapyramidal symptoms than aripiprazole. Article Title: Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trial Article Snippet: .. Cognition was assessed using a set of neuropsychological tests from the Clinical Proteomics:Article Title: Neuroactive steroids, compositions, and uses thereof Article Snippet: To determine the pharmacokinetic (PK) profile of multiple doses of Compound 9 Oral Solution as assessed by the calculation of standard PK parameters; To investigate concentrations of Compound 9 metabolites in plasma and urine after multiple oral dosing; To investigate the pharmacodynamic effects of multiple doses of Compound 9 Oral Solution as assessed by psychomotor testing (Cogstate Early Phase Battery consisting of Detection Task, Identification Task, One Card Learning Task, and Groton Maze Learning Test), mood, anxiety and depression (the Bond-Lader VAS and Hospital Anxiety and Depression Scale), drug likeability (the Drug Effects Questionnaire—5), and electroencephalography (EEG) with eye tracking; To investigate whether Compound 9 Oral Solution induces the metabolism of drugs metabolized via the CYP3A4 and CYP2B6 pathways as assessed by dosing simvastatin and bupropion before and after exposure to Compound 9 in the Drug-Drug-Interaction (DDI) Cohort. .. To determine the pharmacokinetic (PK) profile of multiple doses of Compound 9 Oral Solution as assessed by the calculation of standard PK parameters; To investigate concentrations of Compound 9 metabolites in plasma and urine after multiple oral dosing; To investigate the pharmacodynamic effects of multiple doses of Compound 9 Oral Solution as assessed by psychomotor testing ( |